Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 2/2018

Open Access 01-12-2018 | Review

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review

Authors: William Fusi-Rubiano, Rebecca R. Blow, Mark Lane, Rupal Morjaria, Alastair K. Denniston

Published in: Ophthalmology and Therapy | Issue 2/2018

Login to get access

Abstract

Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion of patients who maintain persistent DMO and have minimal response to anti-VEGF treatment. Iluvien (fluocinolone acetonide 0.19 mg [FAc]) is an important additional treatment option for DMO. In this review we describe the clinical context and the evidence for the use of the FAc implant in treating DMO, from pilot to randomized controlled studies, to later phase real world data. These studies indicate that the FAc implant is effective, well tolerated and a cost-effective option in the treatment of insufficiently responsive DMO.
Literature
1.
2.
3.
Romero-Aroca P. Managing diabetic macular edema: the leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98–104.CrossRef
4.
Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond). 2015;29(9):1115.CrossRef
5.
Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2–3):309–15.CrossRef
6.
Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.CrossRef
7.
Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corti-costeroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–4.CrossRef
8.
9.
10.
Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.CrossRef
11.
Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–35.CrossRef
12.
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.CrossRef
13.
Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014;121(10):1892–903.CrossRef
14.
Yang Y, Bailey C, Holz FG, Eter N, Weber M, Baker C, Kiss S, Menchini U, Moreno JR, Dugel P, Lotery A. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. Eye (Lond). 2015;29(9):1173–80.CrossRef
15.
Parrish RK, Campochiaro PA, Pearson PA, Green K, Traverso CE, FAME Study Group. Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. Ophthalmic Surg Lasers Imaging. Retina. 2016;47(5):426–35.
16.
Parrish RK, Traverso CE, Green K, Dabis RP, FAME Study Group. Quantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implants. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5):418–25.CrossRef
17.
18.
19.
20.
21.
Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Therapy. 2015;4(1):51–8.CrossRef
22.
Elaraoud I, Andreatta W, Kidess A, Bhatnagar A, Tsaloumas M, Quhill F, Yang Y. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16(1):3.CrossRef
23.
Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN®) in patients with diabetic macular edema. Ophthalmol Therapy. 2016;5(1):95–104.CrossRef
24.
Elaraoud I, Quhill H, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (Iluvien®) in patients with diabetic macular edema: 10 eyes with 12 months follow-up. Ophthalmol Therapy. 2016;5(1):105–9.CrossRef
25.
Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol (Auckland, NZ). 2016;10:1257.CrossRef
26.
Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye (Lond). 2017;31(4):650.CrossRef
27.
Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166–72.CrossRef
28.
El-Ghrably I, Steel DH, Habib M, Vaideanu-Collins D, Manvikar S, Hillier RJ. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol. 2017;27(3):357.CrossRef
29.
Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33[Suppl 2]:5–17.CrossRef
30.
Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33[Suppl 2]:19–31.CrossRef
31.
Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33[Suppl 2]:33–43.CrossRef
32.
Quhill H, Quhill F. Real-life ILUVIEN (Fluocinolone Acetonide) case study: rapid drying of the macula and improved vision within 2 years after therapy Initiation. Case Rep Ophthalmol. 2016;7(3):579–85.CrossRef
33.
Fusi-Rubiano W, Mukherjee C, Lane M, Tsaloumas MD, Glover N, Kidess A, Denniston AK, Palmer HE, Manna A, Morjaria R. Treating diabetic macular oedema (DMO): real world UK clinical outcomes for the 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien™) at 2 years. BMC Ophthalmol. 2018;18(1):62.CrossRef
34.
Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53(9):5877–80.CrossRef
35.
Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy prior to anti-vascular endothelial growth factor therapy. Retina. 2015;35(12):2516–28.CrossRef
36.
Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2011;52(7):4605–9.CrossRef
37.
Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM. Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31(5):915–23.CrossRef
38.
Kumar A, Alfahad Q, Mitra A, Elsherbiny S, Lip PL. Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes. Eye (Lond). 2016;30(5):763.CrossRef
39.
Meireles A, Goldsmith C, El-Ghrably I, Erginay A, Habib M, Pessoa B, Coelho J, Patel T, Tadayoni R, Massin P, Atorf J. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye (Lond). 2017;31(5):684–90.CrossRef
40.
Pessoa B, Coelho J, Correia N, Ferreira N, Beirão M, Meireles A. Fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthal Res. 2018;59(2):68–75.CrossRef
41.
Moisseiev E, Morse LS. Fluocinolone acetonide intravitreal implant in the visual axis. JAMA Ophthalmol. 2016;134(9):1067–8.CrossRef
42.
43.
Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, Ma J, Ho AC, Patel V, Whitcup SM, Dugel PU. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;1(172):72–9.CrossRef
44.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, Jonas J, Larsen M, Tadayoni R, Loewenstein A. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.CrossRef
45.
Ch’ng SW, Brent AJ, Empeslidis T, Konidaris V, Banerjee S. Real-world cost savings demonstrated by switching patients with refractory diabetic macular edema to intravitreal fluocinolone acetonide (Iluvien): a retrospective cost analysis study. Ophthalmol Therapy. 2017;10:1–8.
46.
47.
Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203.CrossRef
48.
Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045–53.CrossRef
49.
Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939–46
Metadata
Title
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
Authors
William Fusi-Rubiano
Rebecca R. Blow
Mark Lane
Rupal Morjaria
Alastair K. Denniston
Publication date
01-12-2018
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 2/2018
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-018-0145-7

Other articles of this Issue 2/2018

Ophthalmology and Therapy 2/2018 Go to the issue

Review

Genetic Aspects of Keratoconus: A Literature Review Exploring Potential Genetic Contributions and Possible Genetic Relationships with Comorbidities

Review

Clinical Management of Ocular Surface Squamous Neoplasia: A Review of the Current Evidence

Review

The Routine Use of Intracameral Antibiotics to Prevent Endophthalmitis After Cataract Surgery: How Good is the Evidence?

Original Research

Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting

Original Research

Prospective, Non-randomized, 36-Month Study of Second-Generation Trabecular Micro-Bypass Stents with Phacoemulsification in Eyes with Various Types of Glaucoma

Original Research

Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits